News
Displaying 41–50 of 508
-
Recording Available: Foundation Insights Forum – August 29, 2024
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on August 29, 2024.
-
Summary of the Ninth Annual Retinal Cell & Gene Therapy Innovation Summit 2024
Foundation NewsIn its ninth year, the Innovation Summit featured more than 30 presentations from retina experts from around the world with nearly 420 people in attendance.
-
Foundation Fighting Blindness Comments on Proposed NIH Reforms
Foundation NewsThe Foundation responds to the U.S. House of Representatives Energy and Commerce Committee on the framework for reforming the National Institutes of Health
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Research NewsPreviously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease
-
Genentech to Re-Introduce Susvimo for Wet AMD
Research NewsFDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.
-
Karen Petrou Appointed as Board Chair of the Foundation Fighting Blindness
Foundation NewsDavid Brint retires after eight years of distinguished service; Petrou to lead effective July 1, 2024.
-
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
Research NewsThe company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
ARVO 2024 Highlight: InGel’s Cell Therapy Shows Promise for Preserving Vision
Research NewsThe emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
